Home /  Products /  Aeonose /  Aeonose details /  Uniqueness of the Aeonose

eNose enables non-invasive diagnostics

Using the Aeonose™, diagnostics will become non-invasive, and significantly more time and cost efficient. As the same hardware can be used for several disease diagnostics, the concept is scalable enabling a major market potential. Of course, different diseases will require adapted software.

No painstaking calibration required

The Aeonose™ is the first electronic nose with the ability to avoid chemical calibration after manufacturing and employ a one-time, pre-production calibration instead. In that way, it is feasible to transfer an analysis model to a large number of eNoses without any difficulty.

Competing products have sensors that need a recurring chemical calibration in order to give a correct result. This chemical calibration is an expensive, time consuming and frequently recurring aspect of these products. Transfer of the calibration model to other devices is not possible. This hampers mass application.

The absence of post-manufacturing calibration is a pre-requisite for high-volume production of eNoses and only The eNose Company is able to accomplish this. Our procedure has proven to be feasible in practice. For example, the ‘CannaSniffer’ units, developed for identifying cannabis, have been produced and calibrated in this way, as well as a scorch detection unit.

Suitable for large-scale production

The use of electronic components enables manufacturing our diagnostic device economically. Therefore, it is suitable for high-volume, low-cost production. At the same time, the eNose is robust and suitable for being used in harsh environments.

For different diseases, only minor modifications of the hardware are expected. In case it ends up as a consumer product (e.g. in the case of diabetes), we will develop a special consumable as it will only be necessary to replace a part of it a couple of times a day.

Unique Selling Points

In sum, the Aeonose™ product is unique in several ways, because of its:

  • Non-invasiveness
  • Scalability;
  • Low-cost production;
  • Absence of the need for highly trained personnel;
  • Speed of diagnosing;
  • Build quality;
  • No contamination risks of DNA (competing PCR-methods).